Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder

NCT00662909 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00662909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00662909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
March 28, 2008
Completion date
April 22, 2009
Enrollment
2,149 (actual)
Sites
125

Conditions

As the registry lists them; a condition with its own page is linked.

urinary bladder, overactive